Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Where Will It End? Lilly’s US Price Concessions Increase 30% In 2016

Executive Summary

Eli Lilly recorded $7.69bn in rebates and discounts in the US in 2016 as pharmacy benefit managers demanded greater price concessions in crowded categories like diabetes.

You may also be interested in...



Lilly's Prices After Concessions Rise 6% In 2017, While Merck's Net Prices Decline

Price transparency reports from the big pharmas also show continued increases in price concessions in 2017, but a slow-down in list price increases.

Lilly's Prices After Concessions Rise 6% In 2017, While Merck's Net Prices Decline

Price transparency reports from the big pharmas also show continued increases in price concessions in 2017, but a slow-down in list price increases.

US Retail Drug Spending Growth Slows Substantially In 2016

Retail drug spending rose just 1.3% in 2016, following growth rates of 8.9% and 12.4% in 2015 and 2014, respectively. Moderating trend is reported just ahead of two congressional hearings on drug pricing.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS120147

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel